Search results
147 Results for 'Cancer'
- Technologies (11)
- Collaborations (1)
- Team (0)
- News (100)
- Events (0)
- Multimedia (35)
- Publications (0)
- Jobs (0)
Technologies 11
-
SomaCode: Getting Cell Therapies Where They Need to Go
SomaCode is solving the problem of cell therapy delivery by identifying unique molecular “zip codes” for disease and engineering cells to home to those zip codes, making cell therapies safer and more effective. -
Cellular “Backpacks” to Slow Tumor Growth
Macrophages are the body’s multipurpose defense agents, patrolling for pathogens and engulfing cellular debris, foreign substances, microbes, and even cancer cells. But cancerous tumors have evolved an insidious defense mechanism: they can switch arriving macrophages from an anti-cancer state to a pro-cancer state, in which they help promote the tumor’s growth. As a result, attempts... -
FcMBL: Broad-Spectrum Pathogen Capture for Infectious Diseases
Microbial infection is the cause of life-threatening cases of sepsis, meningitis and multiple other diseases that are major causes of death world-wide. Equally prevalent are pathogenic contaminants in our environment, food, and manufacturing processes. In each case, the presence of dangerous microbes must be confirmed, and when they are found, they need to be removed,... -
Biomaterial Scaffolds for T Cell Expansion
Immunotherapy, or tweaking the body’s own immune system to treat disease, is attracting significant attention in the medical field for its potential to offer long-lasting cures with fewer side effects than chemotherapy or other drugs. One type of immunotherapy involves isolating T cells (a type of white blood cell) from a patient’s body, sometimes modifying... -
Implantable Cancer Vaccine
The implantable cancer vaccine is an aspirin-sized disc that is implanted under the skin and serves as an artificial lymph node, recruiting and training a patient's own immune cells to find and kill their cancer cells. It was validated in a Phase I clinical trial at the Wyss Institute, and is currently being developed by Novartis to treat melanoma. -
Microfluidic Drug Encapsulation
Because of their large molecular sizes and properties, biologic drugs, be it in the form of monoclonal antibodies that target disease-associated molecules or active proteins and enzymes that may correct deficiencies in the human body, have proven difficult to deploy in many cases. Their therapeutic effects on target cells and tissues often require high and...
Collaborations 1
i3 Center: Biomaterials to Create T Cell ImmunityNews 100
Multimedia 35
-
Video/AnimationDoriVac: Square Block DNA Origami VaccineThis animation explains how DoriVac leverages DNA origami nanotechnology and immune activators to stimulate stronger and long-lasting immune responses against cancer and potentially infectious diseases. Credit: Wyss Institute at Harvard University -
Video/AnimationEliminating brain cancer at its source | Natalie Artzi | TEDxMITGlioblastoma is a lethal, aggressive brain cancer with a dismal median overall survival rate of 15 months, a number that has remained unchanged for decades. Treatment for this devastating disease involves surgical resection followed by chemotherapy and radiation therapy; however, tumor recurrence is inevitable as it is impossible to eliminate all tumor cells with current... -
Video/AnimationSomaCode: GPS for Cell TherapyJust like zip codes help drivers navigate to specific addresses using a GPS system, the molecular ‘zip codes’ identified via the SomaCode platform can be used to deliver cell therapies to their specific targets in the human body, increasing the therapies’ efficacy and reducing side effects. Credit: Wyss Institute at Harvard University -
Audio/PodcastBIOS Podcast – Accelerating Diagnostics Innovation with David Walt – Professor at Harvard, Core Faculty member at the Wyss InstituteDavid Walt is the Hansjörg Wyss Professor of Bioinspired Engineering at Harvard Medical School, Professor of Pathology at Harvard Medical School & Brigham and Women’s Hospital, Core Faculty Member of the Wyss Institute at Harvard University, Associate Member at the Broad Institute, Howard Hughes Medical Institute Professor, and is co-Director of the Mass General Brigham... -
Audio/PodcastImmunoengineering with Dave Mooney – BIOS PodcastWyss Core Faculty member Dave Mooney is a leader in the fields of biomaterials, mechanotransduction, drug delivery, tissue engineering and immunoengineering. He is interested in understanding how cells sense signals in their environment and how this alters cell behavior. His laboratory develops biomaterials that exploit these signals to regulate specific cells and their function. They... -
Video/Animation2021 Kabiller Prize in Nanoscience and NanomedicineDavid R. Walt, a Wyss Core Faculty member, member of the faculty at Harvard Medical School in the Department of Pathology, and a Howard Hughes Medical Institute Professor, is the winner of the 2021 Kabiller Prize in Nanoscience and Nanomedicine, the world’s largest monetary award for outstanding achievement in the field of nanotechnology and its...